TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26911833

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (systolic blood pressure goal <120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard control (systolic blood pressure goal <140 mm Hg)
Number of subjects: 9361
Study: 24290367

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: LLD + MCI
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Controls (never-depressed cognitively normal elderly)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Time effect on BDNF levels
Number of subjects: 160
Study: 22914621

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-1903
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCH900271
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GPR109A agonism (via niacin, MK-1903, or SCH900271)
Number of subjects: 0
Study: 20551965

Group type: EXPERIMENTAL
Intervention: Salmon (3 x 150 g/week, 2.1 g LC n-3 PUFA per day)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cod (3 x 150 g/week, 0.3 g LC n-3 PUFA per day)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (1.3 g LC n-3 PUFA per day)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study: 18222358

Group type: EXPERIMENTAL
Intervention: Dobutamine stress test (DST) with gadolinium-enhanced CMR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Coronary flow response (CFR) to adenosine (140 microg/kg/min for 90 s)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CFR comparison in CSX patients with and without DST-induced myocardial perfusion defects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation between CFR to adenosine and DST perfusion defect score on CMR
Number of subjects: 18
Study: 16451374

Group type: EXPERIMENTAL
Intervention: Test whitening toothpaste
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 24
Study: 12657379

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10584056

Group type: EXPERIMENTAL
Intervention: Fine lipid emulsion (0.7 microm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coarse lipid emulsion (10 microm)
Number of subjects: 0
Study: 8905437

Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg body weight, 30 min prior to measurement of GCTT
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (non-cisapride group)
Number of subjects: 21
Study: 1678921

Group type: EXPERIMENTAL
Intervention: Terazosin 5 mg
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Terazosin 10 to 40 mg
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Terazosin 1 to 5 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 7048339

Group type: EXPERIMENTAL
Intervention: 0.2% dithranol and urea cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1% dithranol and urea cream
Number of subjects: 20
Study: 30861163

Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplement during 4 weeks of induction treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo supplement during 4 weeks of induction treatment
Number of subjects: 62
Study: 31029655

Group type: EXPERIMENTAL
Intervention: Women at 13-15 weeks gestation
Number of subjects: 156

Group type: COMPARATOR
Intervention: Women at 15.1-20 weeks gestation
Number of subjects: 156
Study: 28323574

Group type: EXPERIMENTAL
Intervention: Increased calorie breakfast (Binc; ∼2100 kJ)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Habitual breakfast (Bhab; ∼1100 kJ)
Number of subjects: 7
Study: 25267980

Group type: EXPERIMENTAL
Intervention: AS-AQ-MB
Number of subjects: 221

Group type: COMPARATOR
Intervention: AS-AQ
Number of subjects: 221
Study: 23453178

Group type: EXPERIMENTAL
Intervention: Community Diabetes Education (CoDE) program over 12 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual medical care from clinic physicians (Control)
Number of subjects: 180
Study: 21536541

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cafergot
Number of subjects: 42
Study: 18004586

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 30
Study: 16230329

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste (1400 ppm F) and mouthrinse (250 ppm F)
Number of subjects: 115

Group type: COMPARATOR
Intervention: NaF toothpaste (1400 ppm F) and mouthrinse (250 ppm F)
Number of subjects: 115
Study: 12770854

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm NO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (nitrogen)
Number of subjects: 84
Study: 11199240

Group type: EXPERIMENTAL
Intervention: Stepwise-information group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Simultaneous-information group
Number of subjects: 68
Study: 9022539

Group type: EXPERIMENTAL
Intervention: Cafestol (61-64 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cafestol plus kahweol (cafestol 60 mg/d and kahweol 48-54 mg/d)
Number of subjects: 10
Study: 8242109

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3899033

Group type: EXPERIMENTAL
Intervention: Piracetam (1600 mg 3 times a day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times a day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of piracetam and pentoxifylline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29974220

Group type: EXPERIMENTAL
Intervention: Single ureteral stenting
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tandem ureteral stenting
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 104
Study: 29953408

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28216271

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 29
Study: 26004290

Group type: EXPERIMENTAL
Intervention: Multi-component dyadic intervention (eight home visits during three months, combining physical exercise and support)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Monthly information bulletins and phone calls (comparison group)
Number of subjects: 111
Study: 24147061

Group type: EXPERIMENTAL
Intervention: 10 maximal two‐legged hops as conditioning contractions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Drop jumps performed after conditioning hops
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: V‐waves and EMG activity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation between PAP and drop jump rebound height
Number of subjects: 12
Study: 20951543

Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy (TMT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Exposure Therapy Only (EXP)
Number of subjects: 35
Study: 18469642

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous pantoprazole (40 mg q24 hour; 40 mg q12 hour; 80 mg q24 hour; 80 mg q12 hour; 80 mg q8 hour)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Continuous cimetidine infusion (300 mg bolus; 50 mg/h)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: All treatments (pantoprazole and cimetidine)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Pantoprazole and cimetidine
Number of subjects: 202
Study: 16531895

Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein hydrolysate (CHO-PRO: 0.8 g.kg.h carbohydrate and 0.4 g.kg.h protein)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carbohydrate, protein hydrolysate, and free leucine (CHO-PRO-LEU: 0.8 g.kg.h carbohydrate, 0.4 g.kg.h protein, and 0.1 g.kg.h leucine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carbohydrate (CHO: 0.8 g.kg.h)
Number of subjects: 14
Study: 14517527

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 33

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 33
Study: 11489769

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 400

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 400
Study: 9547839

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 8

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 8
Study: 8041414

Group type: EXPERIMENTAL
Intervention: Coronary-stent placement
Number of subjects: 410

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 410
Study: 3173919

Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine 5.0 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine 7.5 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral bromocriptine 2.5 mg
Number of subjects: 11
Study: 28739904

Group type: EXPERIMENTAL
Intervention: Recalling emotions of anxiety and fear connected to experiences of violence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recalling joyful or emotionally neutral experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory experiment recalling violent events
Number of subjects: 0
Study: 25802434

Group type: EXPERIMENTAL
Intervention: Mass test and treatment (MTAT) intervention; three rounds; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 22890477

Group type: EXPERIMENTAL
Intervention: High bandwidth (1.5 Mbps)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Medium bandwidth (256 kbps)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low bandwidth (64.4 kbps)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of high vs low bandwidth
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of medium vs low bandwidth
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of high vs medium bandwidth
Number of subjects: 19
Study: 20352370

Group type: COMPARATOR
Intervention: 10 mg magnesium per kilogram body weight (Group 1 - sedentary controls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg magnesium per kilogram body weight (Group 2 - tae kwon do athletes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No magnesium supplements (Group 3 - tae kwon do athletes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise (Group 2 and Group 3 - tae kwon do athletes)
Number of subjects: 0
Study: 19851235

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 15
Study: 17915032

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study: 15030101

Group type: EXPERIMENTAL
Intervention: Speech stimuli presented to Group A at a stimulus onset asynchrony (SOA) of 610 msec
Number of subjects: 30

Group type: COMPARATOR
Intervention: Speech stimuli presented to Group B at an SOA of 900 msec
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tone stimuli presented to both groups at an SOA of 610 msec
Number of subjects: 30
Study: 11681651

Group type: EXPERIMENTAL
Intervention: HFA‐134a flunisolide by pMDI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HFA‐134a flunisolide by pMDI plus spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CFC flunisolide pMDI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CFC flunisolide pMDI plus Aerochamber
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HFA pMDI plus spacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFC pMDI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: pMDI plus spacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: pMDI alone
Number of subjects: 12
Study: 9036801

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus testosterone (100 mg intramuscularly every 15 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cyclophosphamide (oral and intravenous) without testosterone
Number of subjects: 15
Study: 8169910

Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation test (AST)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Nonstress test (NST)
Number of subjects: 1300
Study: 31780004

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) bundle therapy combined with conventional treatment for sepsis and AGI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received conventional treatment for sepsis and AGI
Number of subjects: 0
Study: 29482973

Group type: EXPERIMENTAL
Intervention: Standardised intravenous hydration with high dose sodium bicarbonate (1 mL/kg of 8.4% NaHCO3)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standardised intravenous hydration without sodium bicarbonate (control)
Number of subjects: 58
Study: 27095791

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy + depressive relapse active monitoring
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (depressive relapse active monitoring alone)
Number of subjects: 203
Study: 24609624

Group type: EXPERIMENTAL
Intervention: Multiple intravitreal injections of anti-VEGF (more than three injections) in DMR patients
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Multiple intravitreal injections of anti-VEGF (more than three injections) in RVO patients
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (noninjection group) in DMR patients
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (noninjection group) in RVO patients
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Severity of retinal ischemia in DMR and RVO patients
Number of subjects: 331
Study: 23084093

Group type: EXPERIMENTAL
Intervention: Test formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 46
Study: 20036117

Group type: COMPARATOR
Intervention: CMF (oral cyclophosphamide, intravenous methotrexate and 5‐fluorouracil)
Number of subjects: 378
Study: 18677165

Group type: EXPERIMENTAL
Intervention: Daily physical exercise (45 min) at school
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional physical education (2 h/week)
Number of subjects: 92
Study: 15965209

Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation of the centromedian‐parafascicular complex (Ce‐Pf) of the thalamus
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation of the internal part of the globus pallidus (GPi)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation of both Ce‐Pf and GPi
Number of subjects: 1
Study: 12585827

Group type: EXPERIMENTAL
Intervention: Interferon therapy (6 million U three times weekly for 48 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 74
Study: 10472319

Group type: EXPERIMENTAL
Intervention: 200 ppb O3 for 2 hours with intermittent exercise and rest protocol
Number of subjects: 9
Study: 9122015

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (40 healthy men)
Number of subjects: 20
Study: 1928034

Group type: EXPERIMENTAL
Intervention: Omnipaque (non-ionic, iso-osmolar contrast agent)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hexabrix (ionic contrast agent)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hypaque (ionic contrast agent)
Number of subjects: 53
Study: 7042068

Group type: COMPARATOR
Intervention: Chemotherapy (DTIC 250 mg/M2 daily x 5 days + actinomycin-D 2 mg/M2 on day 1 every 3-4 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (same chemotherapy regimen + C. parvum 2 mg/M2 I.V. daily for 14 days before every third cycle and on days 7 and 14 of each cycle)
Number of subjects: 88
Study: 31331579

Group type: EXPERIMENTAL
Intervention: Shiatsu therapy in addition to standard care
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 59
Study: 30830386

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyphenol (PP) intervention
Number of subjects: 0
Study: 26655432

Group type: EXPERIMENTAL
Intervention: ENCERT (Emotion Regulation Training)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Conventional CBT
Number of subjects: 244
Study: 24886541

Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy (T arm)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Telaprevir in combination with peginterferon/ribavirin (TPR arm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Telaprevir monotherapy (T arm) and TPR arm
Number of subjects: 8
Study: 23206461

Group type: EXPERIMENTAL
Intervention: Preincisional parecoxib (40 mg intravenously before skin incision)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postincisional parecoxib (40 mg intravenously after skin incision)
Number of subjects: 0
Study: 20227682

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (LAI)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study: 18586901

Group type: COMPARATOR
Intervention: Standard photodynamic therapy (sPDT) + 4 mg intravitreal triamcinolone (IVTA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduced fluence photodynamic therapy (rPDT) + 4 mg intravitreal triamcinolone (IVTA)
Number of subjects: 40
Study: 16204871

Group type: EXPERIMENTAL
Intervention: Automatic method for fetal cardiac signal reconstruction using independent component analysis (ICA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Classical procedure requiring manual classification of fetal components by an expert investigator
Number of subjects: 70
Study: 12189542

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg m(‐2) i.v. day 1 and gemcitabine 1000 mg m(‐2) i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine treatment
Number of subjects: 53
Study: 10365742

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 48

Group type: COMPARATOR
Intervention: No Heparin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Heparin and No Heparin
Number of subjects: 48
Study: 7621684

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)‐releasing subdermal implants (Norplant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NET‐EN 200mg injectable contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined monthly injectable contraceptives (50mg NET‐EN and 5mg estradiol valerate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined low‐dose oral pills (triphasic and monophasic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copper IUDs
Number of subjects: 0
Study: 2137076

Group type: EXPERIMENTAL
Intervention: 5 mg nebulized salbutamol followed by 0.5 mg ipratropium
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ipratropium followed by salbutamol
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both drugs administered together followed by nebulized saline
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ipratropium given after salbutamol
Number of subjects: 117

Group type: COMPARATOR
Intervention: Combination of drugs
Number of subjects: 117
Study: 7003572

Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg orally
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentazocine 25 mg orally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30536589

Group type: EXPERIMENTAL
Intervention: GSK3342830 (single intravenous doses ranging from 250 to 6000 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: GSK3342830 (repeat intravenous infusions 3 times a day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: GSK3342830 (multiple doses)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study: 30413184

Group type: EXPERIMENTAL
Intervention: Combination treatment of varlilumab plus rituximab
Number of subjects: 40
Study: 27387752

Group type: EXPERIMENTAL
Intervention: 12 months of follow-up at a primary care facility with clinical support from a telemedicine platform
Number of subjects: 280

Group type: COMPARATOR
Intervention: 12 months of follow-up at the same clinic
Number of subjects: 280
Study: 24680759

Group type: EXPERIMENTAL
Intervention: BioEnterics Intragastric Balloon (BIB)
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 1357
Study: 22544225

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MW)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 42
Study: 20381014

Group type: EXPERIMENTAL
Intervention: Imagery processing of worry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal processing of worry
Number of subjects: 0
Study: 18924648

Group type: EXPERIMENTAL
Intervention: TDF/FTC/EFV regimen (1 pill once a day)
Number of subjects: 141
Study: 15804873

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) treatment in combination with buprenorphine (BUP)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) treatment in combination with methadone (Meth)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 12727155

Group type: EXPERIMENTAL
Intervention: Bicycle exercise training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of the legs
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bicycle exercise training and FES combined
Number of subjects: 46
Study: 11108211

Group type: EXPERIMENTAL
Intervention: Neural network prediction of LV mass
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Neural network prediction of LVH
Number of subjects: 317